BET Inhibition as a Rational Therapeutic Strategy for Invasive Lobular Breast Cancer.

Louise WalshKathryn E Haley Bruce MoranBrian MooneyFinbarr TarrantStephen F MaddenAlessandra Di GrandeYue FanSudipto DasOscar M RuedaCatríona M DowlingDamir VarešlijaSuet-Feung ChinSabine LinnLeonie S YoungKarin JirströmJohn P CrownRene BernardsCarlos CaldasWilliam M GallagherDarran P O'ConnorTríona Ní Chonghaile

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2019)

We provide evidence that BETi either alone or in combination with FGFR1 inhibitors or BH3 mimetics may be a useful therapeutic strategy for recurrent ILC patients.

Keyphrases

end stage renal disease
ejection fraction
chronic kidney disease
newly diagnosed
prognostic factors
peritoneal dialysis
patient reported outcomes
patient reported
nk cells